These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 34043024)
1. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance. Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024 [TBL] [Abstract][Full Text] [Related]
2. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma. Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106 [TBL] [Abstract][Full Text] [Related]
3. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727 [TBL] [Abstract][Full Text] [Related]
4. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma. Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110 [TBL] [Abstract][Full Text] [Related]
6. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Chen RL; Reynolds CP; Seeger RC Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma. Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682 [TBL] [Abstract][Full Text] [Related]
8. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481 [TBL] [Abstract][Full Text] [Related]
9. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293 [TBL] [Abstract][Full Text] [Related]
10. Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy. Iguchi M; Yagyu S; Kambe K; Higashi M; Fumino S; Kishida T; Iehara T; Mazda O; Tajiri T Anticancer Res; 2023 Jun; 43(6):2417-2424. PubMed ID: 37247922 [TBL] [Abstract][Full Text] [Related]
11. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. Hank JA; Surfus J; Gan J; Chew TL; Hong R; Tans K; Reisfeld R; Seeger RC; Reynolds CP; Bauer M J Immunother Emphasis Tumor Immunol; 1994 Jan; 15(1):29-37. PubMed ID: 8110728 [TBL] [Abstract][Full Text] [Related]
12. Clinically effective monoclonal antibody 3F8 mediates nonoxidative lysis of human neuroectodermal tumor cells by polymorphonuclear leukocytes. Kushner BH; Cheung NK Cancer Res; 1991 Sep; 51(18):4865-70. PubMed ID: 1654202 [TBL] [Abstract][Full Text] [Related]
13. Activation of cellular cytotoxicity and complement-mediated lysis of melanoma and neuroblastoma cells in vitro by murine antiganglioside antibodies MB 3.6 and 14.G2a. Mayer P; Handgretinger R; Bruchelt G; Schaber B; Rassner G; Fierlbeck G Melanoma Res; 1994 Apr; 4(2):101-6. PubMed ID: 8069095 [TBL] [Abstract][Full Text] [Related]
14. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells. Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I Front Immunol; 2024; 15():1382931. PubMed ID: 38736882 [TBL] [Abstract][Full Text] [Related]
15. SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells. Bahri M; Kailayangiri S; Vermeulen S; Galopin N; Rossig C; Paris F; Fougeray S; Birklé S Cancer Immunol Immunother; 2022 Jan; 71(1):71-83. PubMed ID: 34023958 [TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro. Kawashima I; Tada N; Fujimori T; Tai T J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721 [TBL] [Abstract][Full Text] [Related]
17. Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8. Zhao Q; Ahmed M; Guo HF; Cheung IY; Cheung NK J Biol Chem; 2015 May; 290(21):13017-27. PubMed ID: 25851904 [TBL] [Abstract][Full Text] [Related]
18. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105 [TBL] [Abstract][Full Text] [Related]